Statement: Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events.
Primary_evidence: Adverse Events 1:   Total: 17/94 (18.09%)   Anaemia 2/94 (2.13%)   Lymphadenopathy 0/94 (0.00%)   Angina pectoris 0/94 (0.00%)   Ischaemic cardiomyopathy 0/94 (0.00%)   Myocardial infarction 1/94 (1.06%)   Haemorrhoids 1/94 (1.06%)   Ileus 1/94 (1.06%)   Nausea 1/94 (1.06%)   Vomiting 1/94 (1.06%)   Asthenia 1/94 (1.06%)   Disease progression 0/94 (0.00%)   Oedema peripheral 1/94 (1.06%) Adverse Events 2:   Total: 9/39 (23.08%)   Anaemia 2/39 (5.13%)   Lymphadenopathy 0/39 (0.00%)   Angina pectoris 0/39 (0.00%)   Ischaemic cardiomyopathy 0/39 (0.00%)   Myocardial infarction 1/39 (2.56%)   Haemorrhoids 1/39 (2.56%)   Ileus 1/39 (2.56%)   Nausea 1/39 (2.56%)   Vomiting 1/39 (2.56%)   Asthenia 1/39 (2.56%)   Disease progression 0/39 (0.00%)   Oedema peripheral 1/39 (2.56%)